Approach
Our approach takes advantage of state-of-the-art post-genomic era technologies, utilising molecular profiling methods and computational analysis in an unbiased manner to gather data and generate novel hypotheses. The Bahn group has conducted extensive 'omics' studies (transcriptomics, metabolomics and proteomics) on post mortem brain and peripheral tissues and has developed new scientific hypotheses relating to the pathophysiology of schizophrenia, bipolar affective disorder, and other neuropsychiatric conditions. Over the last years our research focus has moved to the identification of biomarkers/surrogate markers in accessible tissues such as blood and cerebrospinal fluid, in order to test these hypotheses in patients and to identify biomarkers with diagnostic and therapeutic value.
Our research is patient-focused, always keeping in mind the clear aim of improving the treatment and outcome of patients affected by these devastating disorders.
